MLN0905

MLN0905 is a potent, orally active Polo-like kinase 1 (PLK1) inhibitor. MLN0905 has inhibitory potency against PLK1 with an IC50 value of 2 nM. MLN0905 can be used for the research of cancer[1][2].

Product Specifications

CAS Number

[1228960-69-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319, H335

Target

Polo-like Kinase (PLK)

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage

Applications

Cancer-Kinase/protease

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/MLN0905.html

Purity

99.94

Solubility

DMSO : ≥ 30 mg/mL

Smiles

CC1=NC=C(CCCN(C)C)C=C1NC2=NC(C(C=CC(C(F)(F)F)=C3)=C3NC(C4)=S)=C4C=N2

Molecular Formula

C24H25F3N6S

Molecular Weight

486.56

Precautions

H302, H315, H319, H335

References & Citations

[1]Duffey MO, et al. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905) . J Med Chem. 2012 Jan 12;55 (1) :197-208.|[2]Shi JQ, et al. MLN0905, a small-molecule plk1 inhibitor, induces antitumor responses in human models of diffuse large B-cell lymphoma. Mol Cancer Ther. 2012 Sep;11 (9) :2045-53.